Gregory Wolf

Professor

University of Michigan
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Background: The updated American Joint Committee on Cancer (AJCC) 8th Edition staging manual restructured nodal classification and staging by placing less prognostic emphasis on nodal metastases for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). However, there was no change for HPV-negative OPSCC. The purpose of our study is to examine the impact of nodal metastases on survival in HPV-negative OPSCC. Methods: HPV-negative OPSCC was queried from the National Cancer Database (NCDB) and Surveillance, Epidemiology and End Results program (SEER) databases. Univariable and multivariable models were utilized to determine the impact of nodal status on overall survival. These patients were reclassified according to AJCC 8 HPV-positive criteria (TNM 8+ ) and risk stratification was quantified with C-statistic. Results: There were 11,147 cases of HPV-negative OPSCC in the NCDB and 3,613 cases in SEER that were included in the nodal classification analysis. Unlike nonoropharyngeal malignancies, increased nodal stage is not clearly associated with survival for patients with OPSCC independent of HPV status. When the TNM 8+ was applied to HPV-negative patients, there was improved concordance in the NCDB cohort, 0.561 (plus minus) 0.004 to 0.624 (plus minus) 0.004 (difference +0.063) and the SEER cohort, 0.561 (plus minus) 0.008 to 0.625 (plus minus) 0.008 (difference +0.065). Conclusions: We demonstrated a reduced impact of nodal metastasis on OPSCC survival, independent of HPV status and specific to OPSCC. Impact: We demonstrate, for the first time that when nodal staging is deemphasized as a part of overall staging, we see improved concordance and risk stratification for HPV-negative OPSCC. The exact mechanism of this differential impact remains unknown but offers a novel area of study.

Year:

2025

Human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is now the leading HPV+ cancer in the United States and United Kingdom. Despite high cure rates, a significant subset of patients have aggressive HPV+ OPSCC that recurs; deciphering the underlying mechanisms will identify biomarkers that delineate patient subgroups for personalized treatment. In a comprehensive investigation using complementary clinically-relevant models of HPV+ OPSCC, we demonstrated that elevated expression of a HPV16 E6 spliced isoform (E6*I) compared to full-length E6 (E6FL), is critical for aggressive invasion. Introduction of splice switching oligonucleotides (SSOs) to inhibit E6FL splicing, effectively mitigated invasion. Mechanistic studies revealed that aggressive invasion occurs via E6*I-induced endocytosis of E-cadherin (ECAD) from the cell membrane, consistent with partial epithelial-to-mesenchymal transition (p-EMT). The clinical relevance of this mechanism was validated in patient cohorts where a reduced ratio of E6FL to all E6 splice variants was associated with high p-EMT signature, lower membrane:cell ECAD, and worse recurrence-free survival. Together, our findings show that low membrane:cell ECAD ratio in pre-treatment biopsies of HPV+ OPSCC, could stratify patients according to risk; patients with a low ratio may not be candidates for treatment de-intensification trials. Importantly, since ECAD detection is by immunohistochemistry, which is widely used even in diagnostic pathology laboratories with limited resources, membrane:cell ECAD ratio could be a clinically scalable biomarker. Targeting E6FL splicing with SSOs should be explored further as a logical strategy for therapeutic intervention in patients with HPV+ OPSCC.

Year:

2025

Purpose: Although the association between neural invasion and poor survival in oral cavity squamous cell carcinoma (OSCC) is known, innervating nerve types have not been definitively established; this has confounded mechanistic and translational studies. Therefore, we investigated innervation in human OSCC and further explored these findings in mice. Experimental Design: Sensory, sympathetic, and parasympathetic nerves were identified by IHC and linked to neural phenotypes in 71 patients. Additionally, we investigated sensory innervation of OSCC using neuronal tracing with transcriptomic profiling in transgenic mice. Results: In OSCC, most nerves are exclusively sensory or sensory mixed with other types. The presence of exclusively sensory nerves and mixed sensory and sympathetic nerves was significantly increased within the tumor bulk compared with the margin, whereas mixed sympathetic and parasympathetic nerves were decreased. The proportion of exclusively sensory and mixed sensory and sympathetic perineural invasion–positive nerves was significantly higher, whereas the proportion of mixed sympathetic and parasympathetic nerves was significantly lower than that of perineural invasion–negative nerves. Classification of tumor-innervating trigeminal sensory neurons in mice revealed an increase in Calca + peptidergic nociceptors and reduction in low-threshold mechanoreceptors. Using transgenic reporter mice to verify innervation, we identified that mouse tongue SCC is innervated by Pirt+ and Calca+ nociceptors. Conclusions: This study is the first comprehensive characterization of nerve types in OSCC with classification of innervating trigeminal sensory neurons. Our findings emphasize the importance of sensory innervation in OSCC and are highly relevant for mechanistic and translational studies on treatment strategies.

Year:

2025

Purpose: Locoregionally advanced HPV + oropharyngeal squamous cell carcinoma (OPSCC) has excellent cure rates, although current treatment regimens are accompanied by acute and long-term toxicities. We designed a phase II deescalation trial for patients with HPV + OPSCC to evaluate the feasibility of an upfront neck dissection to individualize definitive treatment selection to improve the quality of life without compromising survival. Patients and Methods: Patients with T1–3, N0–2 HPV + OPSCC underwent an upfront neck dissection with primary tumor biopsy. Arm A included patients with a single lymph node less than six centimeters, with no extracapsular spread (ECS) and no primary site adverse features underwent transoral surgery. Arm B included patients who had two or more positive lymph nodes with no ECS, or those with primary site adverse features were treated with radiation alone. Arm C included patients who had ECS in any lymph node and were treated with chemoradiation. The primary endpoint was quality of life at 1 year compared with a matched historical control. Results: Thirty-four patients were enrolled and underwent selective neck dissection. On the basis of pathologic characteristics, 14 patients were assigned to arm A, 10 patients to arm B, and 9 to arm C. A significant improvement was observed in Head and Neck Quality of Life (HNQOL) compared with historical controls (−2.6 vs. −11.9, P = 0.034). With a median follow-up of 37 months, the 3-year overall survival was 100% and estimated 3-year estimated progression-free survival was 96% [95% confidence interval (CI), 76%–99%]. Conclusions: A neck dissection–driven treatment paradigm warrants further research as a deintensification strategy.

Year:

2024

Purpose: Locoregionally advanced HPV + oropharyngeal squamous cell carcinoma (OPSCC) has excellent cure rates, although current treatment regimens are accompanied by acute and long-term toxicities. We designed a phase II deescalation trial for patients with HPV + OPSCC to evaluate the feasibility of an upfront neck dissection to individualize definitive treatment selection to improve the quality of life without compromising survival. Patients and Methods: Patients with T1–3, N0–2 HPV + OPSCC underwent an upfront neck dissection with primary tumor biopsy. Arm A included patients with a single lymph node less than six centimeters, with no extracapsular spread (ECS) and no primary site adverse features underwent transoral surgery. Arm B included patients who had two or more positive lymph nodes with no ECS, or those with primary site adverse features were treated with radiation alone. Arm C included patients who had ECS in any lymph node and were treated with chemoradiation. The primary endpoint was quality of life at 1 year compared with a matched historical control. Results: Thirty-four patients were enrolled and underwent selective neck dissection. On the basis of pathologic characteristics, 14 patients were assigned to arm A, 10 patients to arm B, and 9 to arm C. A significant improvement was observed in Head and Neck Quality of Life (HNQOL) compared with historical controls (−2.6 vs. −11.9, P = 0.034). With a median follow-up of 37 months, the 3-year overall survival was 100% and estimated 3-year estimated progression-free survival was 96% [95% confidence interval (CI), 76%–99%]. Conclusions: A neck dissection–driven treatment paradigm warrants further research as a deintensification strategy.

Year:

2024

Collaborators (15)

Thomas Carey

Professor

University of Michigan Medical School

UNITED STATES
View details

Joshua Emrick

Assistant Profesor

University of Michigan

UNITED STATES
View details

Steven B. Chinn

Assistant Professor

University of Michigan

UNITED STATES
View details

Laura Rozek

Professor

Georgetown University

UNITED STATES
View details

Michelle M. Chen

Stanford University

UNITED STATES
View details

Keith Casper

-

UNITED STATES
View details

Huira Kopera

University of Michigan

UNITED STATES
View details

Nisha D'Silva

Professor

University of Michigan

UNITED STATES
View details

Matthew E. Spector

University of Pittsburgh Medical Center

UNITED STATES
View details

Paul Swiecicki

University of Michigan

UNITED STATES
View details

Brian Constantinescu

University of Michigan–Ann Arbor

UNITED STATES
View details

Allison Furgal

Statistician Senior

University of Michigan

UNITED STATES
View details

Peng Li

Associate Professor

University of Michigan

UNITED STATES
View details

Andrew Rosko

University of Michigan

UNITED STATES
View details

Carol Bradford

Dean

Ohio State University

UNITED STATES
View details